Lifastuzumab vedotin

{{Short description|Pharmaceutical drug}}

{{Drugbox

| type = mab

| image = Vedotin_ADCs.svg

| alt =

| mab_type =

| source = zu/o

| target = phosphate-sodium cotransporter

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number = 1401812-88-1

| ATC_prefix = none

| ATC_suffix =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 7IUT83FK6S

| KEGG = D11238

| PubChem =

| DrugBank =

| C=6504 | H=10028 | N=1744 | O=2018 | S=46

| ChemSpiderID = none

| synonyms = DNIB0600A

}}

Lifastuzumab vedotin (INN;{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110 | journal = WHO Drug Information | volume = 27 | issue = 4 | year = 2013 | url =https://www.who.int/medicines/publications/druginformation/innlists/PL111.pdf }} development code DNIB0600A) is an experimental monoclonal antibody-drug conjugate designed for the treatment of cancer.[http://www.ama-assn.org/resources/doc/usan/x-pub/lifastuzumab-vedotin.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Lifastuzumab Vedotin], American Medical Association.

This drug was developed by Genentech/Roche.